Literature DB >> 8522616

alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.

M Conese1, A Nykjaer, C M Petersen, O Cremona, R Pardi, P A Andreasen, J Gliemann, E I Christensen, F Blasi.   

Abstract

The GPI-anchored urokinase plasminogen activator receptor (uPAR) does not internalize free urokinase (uPA). On the contrary, uPAR-bound complexes of uPA with its serpin inhibitors PAI-1 (plasminogen activator inhibitor type-1) or PN-1 (protease nexin-1) are readily internalized in several cell types. Here we address the question whether uPAR is internalized as well upon binding of uPA-serpin complexes. Both LB6 clone 19 cells, a mouse cell line transfected with the human uPAR cDNA, and the human U937 monocytic cell line, express in addition to uPAR also the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP/alpha 2-MR) which is required to internalize uPAR-bound uPA-PAI-1 and uPA-PN-1 complexes. Downregulation of cell surface uPAR molecules in U937 cells was detected by cytofluorimetric analysis after uPA-PAI-1 and uPA-PN-1 incubation for 30 min at 37 degrees C; this effect was blocked by preincubation with the ligand of LRP/alpha 2-MR, RAP (LRP/alpha 2-MR-associated protein), known to block the binding of the uPA complexes to LRP/alpha 2-. MR. Downregulation correlated in time with the intracellular appearance of uPAR as assessed by confocal microscopy and immuno-electron microscopy. After 30 min incubation with uPA-PAI-1 or uPA-PN-1 (but not with free uPA), confocal microscopy showed that uPAR staining in permeabilized LB6 clone 19 cells moved from a mostly surface associated to a largely perinuclear position. This effect was inhibited by the LRP/alpha 2-MR RAP. Perinuclear uPAR did not represent newly synthesized nor a preexisting intracellular pool of uPAR, since this fluorescence pattern was not modified by treatment with the protein synthesis inhibitor cycloheximide, and since in LB6 clone 19 cells all of uPAR was expressed on the cell surface. Immuno-electron microscopy confirmed the plasma membrane to intracellular translocation of uPAR, and its dependence on LRP/alpha 2-MR in LB6 clone 19 cells only after binding to the uPA-PAI-1 complex. After 30 min incubation at 37 degrees C with uPA-PAI-1, 93% of the specific immunogold particles were present in cytoplasmic vacuoles vs 17.6% in the case of DFP-uPA. We conclude therefore that in the process of uPA-serpin internalization, uPAR itself is internalized, and that internalization requires the LRP/alpha 2-MR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522616      PMCID: PMC2120674          DOI: 10.1083/jcb.131.6.1609

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  63 in total

1.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Authors:  M P Stoppelli; A Corti; A Soffientini; G Cassani; F Blasi; R K Assoian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Autocrine saturation of pro-urokinase receptors on human A431 cells.

Authors:  M P Stoppelli; C Tacchetti; M V Cubellis; A Corti; V J Hearing; G Cassani; E Appella; F Blasi
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  On the preparation of cryosections for immunocytochemistry.

Authors:  G Griffiths; A McDowall; R Back; J Dubochet
Journal:  J Ultrastruct Res       Date:  1984-10

5.  A study of positive staining of ultrathin frozen sections.

Authors:  K T Tokuyasu
Journal:  J Ultrastruct Res       Date:  1978-06

6.  The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

Authors:  E Appella; E A Robinson; S J Ullrich; M P Stoppelli; A Corti; G Cassani; F Blasi
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

7.  Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.

Authors:  M V Cubellis; M L Nolli; G Cassani; F Blasi
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

8.  Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.

Authors:  R C Kowal; J Herz; K H Weisgraber; R W Mahley; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

9.  Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I.

Authors:  B L Bergman; R W Scott; A Bajpai; S Watts; J B Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

10.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

View more
  44 in total

1.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

Authors:  R P Czekay; T A Kuemmel; R A Orlando; M G Farquhar
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities.

Authors:  Stéphane Dedieu; Benoît Langlois; Jérôme Devy; Brice Sid; Patrick Henriet; Hervé Sartelet; Georges Bellon; Hervé Emonard; Laurent Martiny
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

4.  Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.

Authors:  Debra J Warejcka; Malathi Narayan; Sally S Twining
Journal:  Exp Eye Res       Date:  2011-07-27       Impact factor: 3.467

5.  Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report.

Authors:  Feiming Ye; Ya Wang; Congqing Wu; Deborah A Howatt; Chia-Hua Wu; Anju Balakrishnan; Adam E Mullick; Mark J Graham; A H Jan Danser; Jian'an Wang; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

6.  Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane.

Authors:  Christian Hellriegel; Valeria R Caiolfa; Valeria Corti; Nicolai Sidenius; Moreno Zamai
Journal:  FASEB J       Date:  2011-05-20       Impact factor: 5.191

7.  Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.

Authors:  Nagarekha Pasupuleti; Ana Cristina Grodzki; Fredric Gorin
Journal:  Mol Pharmacol       Date:  2015-01-29       Impact factor: 4.436

8.  Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.

Authors:  A Nykjaer; E I Christensen; H Vorum; H Hager; C M Petersen; H Røigaard; H Y Min; F Vilhardt; L B Møller; S Kornfeld; J Gliemann
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

9.  beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Authors:  S Hapke; M Gawaz; K Dehne; J Köhler; J F Marshall; H Graeff; M Schmitt; U Reuning; E Lengyel
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

10.  Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.

Authors:  F Vilhardt; M Nielsen; K Sandvig; B van Deurs
Journal:  Mol Biol Cell       Date:  1999-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.